Anzeige
Mehr »
Login
Mittwoch, 08.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
GameStop 2.0? ...alle Anzeichen für den nächsten großen Short Squeeze!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
348 Leser
Artikel bewerten:
(1)

Nintex Named a Leader in The Aragon Research Globe for Digital Transaction Management, 2022

Finanznachrichten News

New report by independent research and advisory firm identifies Nintex as a market leading software provider of advanced Digital Transaction Management (DTM) solutions

LONDON, March 24, 2022 /PRNewswire/ -- Nintex, the global standard for process intelligence and automation, today announced it has been named a leader in The Aragon Research Globe for Digital Transaction Management, 2022 based on a review of 20 major providers in the market by the independent research and advisory firm.

Nintex is the global standard for process management and automation. Today more than 10,000 public and private sector organizations across 90 countries turn to the Nintex Platform to accelerate progress on their digital transformation journeys by quickly and easily managing, automating and optimizing business processes. Learn more by visiting www.nintex.com and experience how Nintex and its global partner network are shaping the future of Intelligent Process Automation (IPA).
  • To download the report, visit https://www.nintex.com/resources/the-aragon-research-globe-for-digital-transaction-management-2022/

In the report, Aragon recognises the increasingly important role of digital transaction management in helping enterprises successfully navigate the COVID era. With many employees still working remotely, the firm says, "Paperless transactions are the way that business gets done, and DTM providers have been a key reason for enterprise success during this time."

"Meeting the digital demands of customers and employees to transform the way people work is just as critical today as it was at the start of the pandemic," said Nintex CEO Eric Johnson. "Nintex is honoured to be named a Leader for the second consecutive year, and our ongoing commitment is to help the global Nintex community of customers and partners turn paper-based and repetitive processes into fully digital experiences with our easy-to-use, intelligent automation platform."

Within the report, Aragon Research examines the complete capabilities of the Nintex Process Platform to eliminate paper and automate end-to-end processes. With Nintex's acquisition of DTM market leader AssureSign in June 2021-now integrated into next-generation Nintex Workflow Cloud and leveraging advanced document automation capabilities in Nintex Drawloop DocGen for Salesforce-customers can automate the assembly and digital distribution of documents across various industries and use cases.

"As a leader in The Aragon Research Globe for Digital Transaction Management 2022, Nintex is well positioned to sustain its growth trajectory," said Aragon Research Lead Analyst, Jim Lundy. "Now with nearly $300 million in annual revenue, Nintex continues to add solutions and capabilities into its suite of process intelligence and automation tools that Center of Excellence (COE) groups need to consider."

Nintex's most recent acquisition in February 2022 of process discovery innovator and RPA leader Kryon will further Nintex's position in the intelligent process automation market and as the process system of record for commercial enterprises and government agencies.

Industry leaders like Zoom, AstraZeneca, and Coca-Cola Beverages Florida, LLC, as well as government agencies and municipalities like the City and County of Denver and the City of Garland, Texas, all report significant results and customer/stakeholder satisfaction leveraging Nintex to easily manage, automate and optimise simple to complex business processes and workflows.

To re-imagine your own business processes and put automation to work - from workflow to document or robotic process automation (RPA) - within your organisation, request a Nintex demo at www.nintex.com/request-demo.

Media Contact
Laetitia Smith
Nintex
laetitia.smith@nintex.com
+64 21 154 7114

About Nintex
Nintex is the global standard for process intelligence and automation. Today more than 10,000 public and private sector organisations across 90 countries turn to the Nintex Process Platform to accelerate progress on their digital transformation journeys by quickly and easily managing, automating and optimising business processes. Learn more by visiting www.nintex.com and experience how Nintex and its global partner network are shaping the future of Intelligent Process Automation (IPA).

Product or service names mentioned herein may be the trademarks of their respective owners.

Aragon Disclaimer
Aragon Research does not endorse vendors, or their products or services that are referenced in its research publications, and does not advise users to select those vendors that are rated the highest. Aragon Research publications consist of the opinions of Aragon Research and Advisory Services organisation and should not be construed as statements of fact. Aragon Research provides its research publications and the information contained in them "AS IS," without warranty of any kind.

Logo - https://mma.prnewswire.com/media/700078/Nintex_Logo.jpg

© 2022 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.